ReviewCells2019
CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 82 citations in OpenAlex.
- Mass Cytometry Reveals Cell Type-specific Immune Remodeling in Placentas of Women with Chronic Hepatitis B Infection.Journal of clinical and translational hepatology · 2026Article
- Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression.Cell biochemistry and biophysics · 2026Review
- Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression.Cell biochemistry and biophysics · 2026Review
- Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression.Cell biochemistry and biophysics · 2026Review
- Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression.Cell biochemistry and biophysics · 2026Review
- Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in Multidrug-Resistant High-Risk Neuroblastoma.International journal of molecular sciences · 2026Article
- Mitochondria: the key hub for hematopoietic stem cell homeostasis maintenance and fate determination.Stem cell research & therapy · 2026Review
- Quaternary Phosphonium Salts Outperformed Vemurafenib (PLX) and Etoposide Against BRAFInternational journal of molecular sciences · 2026Article
- Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas.Scientific reports · 2026Article
- Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study.Transplantation direct · 2026Article
- Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity.International journal of molecular sciences · 2026Review
- CRISPR/Cas9 Technology for Modifying Immune Checkpoint in CAR-T Cell Therapy for Hematopoietic Malignancies.Current gene therapy · 2026Review
- Regulating the regulators via targeting CD38 in the tumor microenvironment.Frontiers in immunology · 2026Review
- Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- A model-free phase I/II dose optimization design for immunotherapy trials.Statistical methods in medical research · 2025Article
- Dysregulation of the Bone Marrow Microenvironment in Pediatric Tumors: The Role of Extracellular Vesicles in Acute Leukemias and Neuroblastoma.International journal of molecular sciences · 2025Review
- Secondary antibody deficiencies: what's around the corner?Frontiers in immunology · 2025Review
- CD38 and the mitochondrial calcium uniporter contribute to age-related hematopoietic stem cell dysfunction.Immunometabolism (Cobham, Surrey) · 2024Article
- Restraining of glycoprotein VI- and integrin α2β1-dependent thrombus formation by platelet PECAM1.Cellular and molecular life sciences : CMLS · 2024Article
- An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer's Disease.Journal of Alzheimer's disease reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD38 is a multifunctional cell surface protein endowed with receptor/enzymatic functions. The protein is generally expressed at low/intermediate levels on hematological tissues and some solid tumors, scoring the highest levels on plasma cells (PC) and PC-derived neoplasia. CD38 was originally described as a receptor expressed by activated cells, mainly T lymphocytes, wherein it also regulates cell adhesion and cooperates in signal transduction mediated by major receptor complexes. Furthermore, CD38 metabolizes extracellular NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.